標(biāo)題: Titlebook: Biomarkers in Inflammatory Bowel Diseases; Nik Sheng Ding,Peter De Cruz Textbook 2019 Springer Nature Switzerland AG 2019 Inflammatory Bow [打印本頁(yè)] 作者: 到凝乳 時(shí)間: 2025-3-21 19:00
書(shū)目名稱Biomarkers in Inflammatory Bowel Diseases影響因子(影響力)
書(shū)目名稱Biomarkers in Inflammatory Bowel Diseases影響因子(影響力)學(xué)科排名
書(shū)目名稱Biomarkers in Inflammatory Bowel Diseases網(wǎng)絡(luò)公開(kāi)度
書(shū)目名稱Biomarkers in Inflammatory Bowel Diseases網(wǎng)絡(luò)公開(kāi)度學(xué)科排名
書(shū)目名稱Biomarkers in Inflammatory Bowel Diseases被引頻次
書(shū)目名稱Biomarkers in Inflammatory Bowel Diseases被引頻次學(xué)科排名
書(shū)目名稱Biomarkers in Inflammatory Bowel Diseases年度引用
書(shū)目名稱Biomarkers in Inflammatory Bowel Diseases年度引用學(xué)科排名
書(shū)目名稱Biomarkers in Inflammatory Bowel Diseases讀者反饋
書(shū)目名稱Biomarkers in Inflammatory Bowel Diseases讀者反饋學(xué)科排名
作者: ABHOR 時(shí)間: 2025-3-21 23:28 作者: 不能約 時(shí)間: 2025-3-22 01:09
Clinical Trial Design to Facilitate Biomarker Discoveryent would be valuable. Data and materials collected in clinical trials are a valuable source for identification of predictive biomarkers or development of pharmacokinetic models. By using a dashboard system with an incorporated pharmacokinetic model, the exact medication dose a patient should receiv作者: 有危險(xiǎn) 時(shí)間: 2025-3-22 04:39
Luminal Crohn’s Diseasertreating those with symptoms unrelated to their CD..Therefore, in addition to assessing clinical symptoms, there is a need to incorporate more objective markers of disease activity into the management of CD. In the pursuit of providing such information, a number of tools have been assessed in their作者: 閑蕩 時(shí)間: 2025-3-22 12:01 作者: 錢(qián)財(cái) 時(shí)間: 2025-3-22 16:48 作者: 獸群 時(shí)間: 2025-3-22 20:58
Refractory Proctitisst of the other potential topical agents is limited to open-labelled studies alone and thus requires a great deal more investigation. The use of systemic, immunomodulatory and biological agents in proctitis is the same as for left-sided and extensive UC. Therapy has undoubtedly improved over recent 作者: 鼓掌 時(shí)間: 2025-3-23 00:53
The Role of Biomarkers in the?Ileal Anal Pouchlp guide clinicians. These biomarkers can help predict those that will develop pouchitis and may therefore be useful as a surveillance strategy to enable prompt treatment before symptoms of pouchitis develop..Despite their potential, no biomarker has been validated for its use in pouchitis, and the 作者: Cervical-Spine 時(shí)間: 2025-3-23 04:24 作者: Soliloquy 時(shí)間: 2025-3-23 07:03
https://doi.org/10.1007/978-3-642-96306-3rgical intervention in CD, compared with proximal disease extension, hospitalization, and colectomy in UC. Age at onset, disease phenotype characteristics (early disease course, behavior and localization/disease extension), smoking status, and accelerated treatment algorithms in early disease were r作者: garrulous 時(shí)間: 2025-3-23 12:06
https://doi.org/10.1007/978-3-642-57930-1ent would be valuable. Data and materials collected in clinical trials are a valuable source for identification of predictive biomarkers or development of pharmacokinetic models. By using a dashboard system with an incorporated pharmacokinetic model, the exact medication dose a patient should receiv作者: CUMB 時(shí)間: 2025-3-23 16:54 作者: 發(fā)出眩目光芒 時(shí)間: 2025-3-23 20:47
https://doi.org/10.1007/978-3-540-70854-4al perianal fistulas. About one-third of patients with perianal Crohn’s fistula respond to antitumour necrosis factor (TNF) agents, but prolonged treatment is usually necessary, and the risk of recurrence is high. Only 34% of patients remained free of relapse after 1?year of treatment. Combination o作者: 運(yùn)動(dòng)吧 時(shí)間: 2025-3-23 22:42 作者: Negotiate 時(shí)間: 2025-3-24 03:06 作者: 翅膀拍動(dòng) 時(shí)間: 2025-3-24 07:57
Anwendung: Das RSA-Kryptosystem,lp guide clinicians. These biomarkers can help predict those that will develop pouchitis and may therefore be useful as a surveillance strategy to enable prompt treatment before symptoms of pouchitis develop..Despite their potential, no biomarker has been validated for its use in pouchitis, and the 作者: AFFIX 時(shí)間: 2025-3-24 12:07 作者: 名字 時(shí)間: 2025-3-24 15:57 作者: explicit 時(shí)間: 2025-3-24 20:27 作者: AGOG 時(shí)間: 2025-3-25 00:08 作者: 沙文主義 時(shí)間: 2025-3-25 06:47
Konjunktursteuerung — eine Illusion?destructive disease that can result in progressive bowel damage and ultimately disability. It mainly affects young adults, causes morbidity, and impacts on quality of life. The majority of patients with CD initially present with an inflammatory phenotype at diagnosis, but over time various complicat作者: BLAZE 時(shí)間: 2025-3-25 08:44
https://doi.org/10.1007/978-3-642-57930-1It has numerous applications within the IBD space. Current day applications include the idea of treating to target goals over a finite timeline and using proactive therapeutic drug monitoring. Future applications are myriad and range from alterations in the microbiome, to advanced modeling to better作者: 說(shuō)笑 時(shí)間: 2025-3-25 12:07
https://doi.org/10.1007/978-3-642-57930-1as clinical disease activity, to patient reported outcomes in combination with objective measurements such as mucosal?improvement. Even though therapeutic options for treatment of IBD are increasing, with many new therapeutic antibodies and small molecules under active investigation, treatment failu作者: 飛鏢 時(shí)間: 2025-3-25 17:07 作者: BOLT 時(shí)間: 2025-3-25 20:02
https://doi.org/10.1007/978-3-540-70854-4fibrostenosing CD and the need for surgery have largely remained unchanged despite the use of anti-inflammatory drugs including biologics. Fibrosis is a common occurrence in ulcerative colitis. Clinical, serologic, and imaging markers lack accuracy to predict, diagnose, and prognosticate fibrostenos作者: idiopathic 時(shí)間: 2025-3-26 03:44 作者: 瑣碎 時(shí)間: 2025-3-26 07:50 作者: 落葉劑 時(shí)間: 2025-3-26 08:46 作者: Conducive 時(shí)間: 2025-3-26 13:40 作者: 油氈 時(shí)間: 2025-3-26 18:52 作者: 遺傳 時(shí)間: 2025-3-26 21:56 作者: 滴注 時(shí)間: 2025-3-27 02:35
Anwendung: Das RSA-Kryptosystem,ilial adenomatous polyposis. Despite overall good long-term function, pouchitis, a nonspecific inflammatory condition in the ileal pouch reservoir, can cause symptoms including increased stool frequency and fluidity, haematochezia, abdominal cramping, urgency and tenesmus, incontinence, fever and ex作者: diathermy 時(shí)間: 2025-3-27 09:03
https://doi.org/10.1007/978-94-010-1628-5nifestations involving multiple organs. These most commonly include articular (axial and appendicular), dermatologic or ophthalmic involvement but can also more rarely include the renal and pulmonary systems. The clinical course can either mirror intestinal disease activity or be independent of it. 作者: MIR 時(shí)間: 2025-3-27 12:00
https://doi.org/10.1007/978-3-030-11446-6Inflammatory Bowel Disease; Genomics; Metatranscriptomics; proteomics; biomarkers; fibrosis; cholangitis; u作者: 法律的瑕疵 時(shí)間: 2025-3-27 16:01
Springer Nature Switzerland AG 2019作者: Loathe 時(shí)間: 2025-3-27 19:06
https://doi.org/10.1007/978-3-540-70854-4/failure and salvage therapy response/failure. It will provide a clinical algorithm encompassing biomarkers to help guide clinical management as well as identify future directions for ongoing research.作者: 狂怒 時(shí)間: 2025-3-27 22:04 作者: 他去就結(jié)束 時(shí)間: 2025-3-28 04:24
http://image.papertrans.cn/b/image/187813.jpg作者: 打算 時(shí)間: 2025-3-28 09:45
Biomarkers in Acute Severe Ulcerative Colitis/failure and salvage therapy response/failure. It will provide a clinical algorithm encompassing biomarkers to help guide clinical management as well as identify future directions for ongoing research.作者: Robust 時(shí)間: 2025-3-28 11:43 作者: AWL 時(shí)間: 2025-3-28 16:37
Clinical Risk Factors: Lessons from Epidemiologychemical, and endoscopic remission, with ultimate outcomes involving prevention of disease progression, surgery, or hospitalization. Thus, risk assessment and prediction of expected disease course by clinical, biochemical, and endoscopic markers has become important in patient stratification, manage作者: 慢跑 時(shí)間: 2025-3-28 19:23 作者: nonsensical 時(shí)間: 2025-3-29 00:38 作者: 人類的發(fā)源 時(shí)間: 2025-3-29 04:52 作者: Infant 時(shí)間: 2025-3-29 10:50
Luminal Crohn’s Diseaseefore, obtaining an accurate assessment of disease activity is paramount for risk-stratifying patients and initiating or escalating therapy when appropriate. Within the classic management paradigm, treatment decisions have been largely predicated on patient-reported symptoms. However, more recent ev作者: 溫和女孩 時(shí)間: 2025-3-29 12:35
Fibrosis and Stricturing Disease in Crohn’s Diseasefibrostenosing CD and the need for surgery have largely remained unchanged despite the use of anti-inflammatory drugs including biologics. Fibrosis is a common occurrence in ulcerative colitis. Clinical, serologic, and imaging markers lack accuracy to predict, diagnose, and prognosticate fibrostenos作者: Increment 時(shí)間: 2025-3-29 15:36
Postoperative Crohn’s Disease. It will discuss the optimal management of Crohn’s disease following resectional surgery with reference to the natural history of Crohn’s disease after surgery, risk factors for earlier postoperative recurrence, diagnosis and monitoring of recurrence and therapeutic strategies to address prevention作者: 財(cái)產(chǎn) 時(shí)間: 2025-3-29 20:56
Perianal Crohn’s Diseasesurgical interventions. Perianal Crohn’s disease involves a spectrum of disorders, from fistulising to non-fistulising disease. The aetiology of perianal Crohn’s disease is not well understood. Several biomarkers including the presence of anti-. antibodies (ASCA) and OmpC antibody and persistently h作者: emission 時(shí)間: 2025-3-30 00:04
Biomarkers in Acute Severe Ulcerative Colitis/failure and salvage therapy response/failure. It will provide a clinical algorithm encompassing biomarkers to help guide clinical management as well as identify future directions for ongoing research.作者: Manifest 時(shí)間: 2025-3-30 07:05
Chronic Active Ulcerative Colitisortant role in understanding the individual disease phenotype. Disease activity should be proactively monitored with the non-invasive biomarkers CRP and faecal calprotectin, in addition to endoscopic assessment to establish mucosal and histological severity. Serial faecal calprotectins are particula作者: Serenity 時(shí)間: 2025-3-30 11:11 作者: 細(xì)頸瓶 時(shí)間: 2025-3-30 12:38 作者: ELATE 時(shí)間: 2025-3-30 16:43
The Role of Biomarkers in the?Ileal Anal Pouchilial adenomatous polyposis. Despite overall good long-term function, pouchitis, a nonspecific inflammatory condition in the ileal pouch reservoir, can cause symptoms including increased stool frequency and fluidity, haematochezia, abdominal cramping, urgency and tenesmus, incontinence, fever and ex作者: fulcrum 時(shí)間: 2025-3-30 22:40
Extra-intestinal Manifestations in Inflammatory Bowel Disease: Diagnosis and Managementnifestations involving multiple organs. These most commonly include articular (axial and appendicular), dermatologic or ophthalmic involvement but can also more rarely include the renal and pulmonary systems. The clinical course can either mirror intestinal disease activity or be independent of it. 作者: 配置 時(shí)間: 2025-3-31 01:06 作者: intoxicate 時(shí)間: 2025-3-31 05:26
https://doi.org/10.1007/978-94-010-1628-5tations may involve treating the underlying condition with some resolving as the bowel inflammation improves. Others may require treatment aimed specifically at the extra-intestinal manifestation. In refractory cases the best evidence tends to be for steroids and anti-TNF agents although other biologics and immunosuppressants may also play a role.
